Understanding APC

Breaking News – FDA Approves another New Treatment for Late Stage Advanced Prostate Cancer – Xtandi (MDV3100)

The U.S. Food and Drug Administration today, August 31, 2012 approved Xtandi® (MDV3100) (enzalutamide) capsules to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Approved for prostate cancer patients previously treated with chemotherapy, Xtandi was reviewed under the FDA’s priority review [...]

By Malecare|2017-10-19T10:50:57-04:00August 31st, 2012|Advanced Prostate Cancer, Chemo Therapy Failure, enzalutamide, FDA, Uncategorized, Understanding APC, Xtandi|0 Comments

A FDA Approval for Zytiga Before Chemotherapy – On the Horizon

On Wednesday, Johnson & Johnson said that the FDA will conduct a fast review of Zytiga as a treatment for men with advanced prostate cancer who have not received chemotherapy. The Food and Drug Administration has agreed to conduct a six-month review of Zytiga which should be completed in mid-December, 2012. According to representatives from [...]

By Malecare|2012-08-31T16:05:51-04:00August 31st, 2012|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

Four New Sites Added to the MDV3100 (Enzalutamide) Early Access Trial

The Early/Expanded Access Committee has informed me that four additional sites have been added to the trial so there are now 23 States that have an expanded access trial of MDV3100 available to men with advanced prostate cancer. The trial is designed to monitor the safety of the drug in men with progressive castration-resistant advanced [...]

By Malecare|2017-10-19T10:50:57-04:00August 20th, 2012|Advanced Prostate Cancer, Drugs & Treatments, Early/Expanded Access Programs, Enzalutamide (MDV-3100), MDV3100, On The Horizon, Uncategorized, Understanding APC|0 Comments

The Debate Continues, Is IAD or CAD Superior for the Treatment of Men with Castrate Resistant Prostate Cancer?

A new randomized study (FinnProstate Study VII) on the merits of intermittent androgen deprivation (IAD) compared to continuous androgen therapy (CAD) contradicts the recent revelations from the last ASCO presentation (Hussain et.al) where the clear conclusion was that CAD was superior to IAD. At the ASCO conference Dr. Hussain’s study concluded that IAD was significantly [...]

By Malecare|2012-08-14T21:30:50-04:00August 14th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|1 Comment

No Reduction in Mortality for Men with Localized Prostate Cancer who had a Prostatectomy

In an updated study published in the New England Journal of Medicine men who had a radical prostatectomy did not enjoy the experience of a reduced all-cause mortality or prostate cancer mortality compared with those men who had only observation through several years of follow-up. The subject men had localized prostate cancer often detected by [...]

By Malecare|2012-08-13T14:08:04-04:00August 13th, 2012|Advanced Prostate Cancer, Drugs & Treatments, General Information, Prostate Ponderings, Research, Uncategorized, Understanding APC|0 Comments

Adding Radiotherapy to ADT Increases Survival for a Man Diagnosed with Locally Advanced Prostate Cancer

Men with locally advanced prostate cancer have a better survival chance if they receive radiotherapy along with androgen deprivation therapy (ADT). This data was presented at the recent American Society of Clinical Oncology (ASCO) 2012 conference. Professor Malcom Mason from Whales University discussed a trial he conducted that demonstrated that for a man diagnosed with [...]

By Malecare|2020-02-04T09:50:33-05:00August 10th, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Uncategorized, Understanding APC|0 Comments

Impact of Postoperative PSA Scores on Recurrence and the use of Salvage Therapy on the Risk of Death

In a study conducted by Choueiri et al. published in Cancer it was suggested that men who have prostate cancer that was treated by a radical prostatectomy (RP) who then had a long time to a biochemical recurrence (BCR) or a long PSA doubling time after a BCR have no higher overall risk of death [...]

By Malecare|2012-08-06T09:43:02-04:00August 6th, 2012|Advanced Prostate Cancer, Bio Chemical Recurrence, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Research, Uncategorized, Understanding APC|0 Comments

The Latest News about MDV3100 (Enzalutamide) – We Believe that Its FDA Approval is Just Around the Corner

My very dear friend and advocate supreme, Jan Manarite, from PCRI has sent me an update on MDV3100 (enzalutamide). As usual her information is important, so I thought I would pass it on today. • She points out that once the FDA approves MDV3100 (I am going to work on the assumption that it will [...]

By Malecare|2012-08-04T12:10:12-04:00August 4th, 2012|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, Enzalutamide (MDV-3100), FDA, General Information, MDV3100, Uncategorized, Understanding APC|0 Comments

No PSA Test Means More Men will be Diagnosed with A Terminal Illness, Advanced Prostate Cancer

Finally, we are getting a little common sense discussion about the role of PSA screening. Not to beat a dead horse, but as we all know the United Sates Preventive Task Force (USPTF) changed their rating of the PSA test from a D to a F. The result of this change is that many doctors, [...]

By Malecare|2012-07-30T16:53:41-04:00July 30th, 2012|Advanced Prostate Cancer, General Information, How We Live, Politics of Cancer, Screening, Uncategorized, Understanding APC|3 Comments

AUA 2012 – The Absence of Goal Setting in the Dialogue between Men with Advanced Prostate Cancer and their Doctors

What are our goals as advanced prostate cancer survivors and what are the goals of our oncologists? Often they are not the same! This misalignment between our expectations and those of our clinicians is common, but inexcusable. These issues become clear when we look at issues surrounding our quality of life. The treatments for advanced [...]

By Malecare|2012-07-28T09:48:59-04:00July 28th, 2012|Advanced Prostate Cancer, AUA, Drugs & Treatments, General Information, How We Live, Uncategorized, Understanding APC|0 Comments